title: I-131-MIBG therapies.
abstract: Metaiodobenzylguanidine (MIBG) is a tracer that selectively targets neuroendocrine cells. On this basis, radiolabeled iodinated-MIBG (I-131-MIBG) has been introduced as a molecular nuclear therapy in the management of neuroendocrine tumors, including neuroblastoma, pheochromocytoma, paraganglioma, neuroendocrine carcinomas, and other rare neuroendocrine tumors. Extensive work has been addressed to develop I-131-MIBG therapy: doses, therapeutic schemes, and efficiency. In this paper, we present an overview on I-131-MIBG therapy, with main focus on different aspects how to perform this treatment.
authors: Department of Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands. stefan.voo@mumc.nl
authors: Stefan
authors: S
authors: Vöö
authors: Jan
authors: J
authors: Bucerius
authors: Felix M
authors: FM
authors: Mottaghy
mesh_terms: D019797:3-Iodobenzylguanidine / Q000008:administration & dosage* / Q000378:metabolism; D000818:Animals; D018278:Carcinoma, Neuroendocrine / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D002986:Clinical Trials as Topic / Q000379:methods; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage* / Q000378:metabolism
chemical_list: D007457:Iodine Radioisotopes; D019797:3-Iodobenzylguanidine